United Therapeutics Corporation Income (Loss) from Continuing Operations, Per Diluted Share
United Therapeutics Corporation (UTHR) reported Income (Loss) from Continuing Operations, Per Diluted Share of $3.28 per share for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2014-02-25
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for the quarter ending 2012-09-30 was $1.46, a 10.61% increase year-over-year.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for the quarter ending 2012-06-30 was $1.34, a 13.56% increase year-over-year.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for the quarter ending 2012-03-31 was $1.29, a 316.13% increase year-over-year.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for the quarter ending 2011-09-30 was $1.32, a 97.01% increase year-over-year.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for fiscal 2013 was $3.28, a 42.56% decline from fiscal 2012.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for fiscal 2012 was $5.71, a 56.01% increase from fiscal 2011.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for fiscal 2011 was $3.66, a 95.72% increase from fiscal 2010.
- United Therapeutics Corporation income (loss) from continuing operations, per diluted share for fiscal 2010 was $1.87, a 450.00% increase from fiscal 2009.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2013-12-31 | $3.28 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $5.71 10-K · filed 2014-02-25 | |||
| 2012-09-30 | $1.46 10-Q · filed 2012-11-01 | $4.11 10-Q · filed 2012-11-01 | ||
| 2012-06-30 | $1.34 10-Q · filed 2012-07-26 | $2.63 10-Q · filed 2012-07-26 | ||
| 2012-03-31 | $1.29 10-Q · filed 2012-04-26 | |||
| 2011-12-31 | $3.66 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $1.32 10-Q · filed 2012-11-01 | $2.80 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | $1.18 10-Q · filed 2012-07-26 | $1.49 10-Q · filed 2012-07-26 | ||
| 2011-03-31 | $0.31 10-Q · filed 2012-04-26 | |||
| 2010-12-31 | $1.87 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $0.67 10-Q · filed 2011-10-27 | $1.63 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $0.63 10-Q · filed 2011-07-28 | $0.96 10-Q · filed 2011-07-28 | ||
| 2009-12-31 | $0.34 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |